Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea 2018 Review: Hopes And Worries Coexist In Pharma Sector

Executive Summary

As the year end approaches, Scrip wraps up what major events made headlines in the South Korean pharma/biotech sector in 2018.

Advertisement

Related Content

Samsung BioLogics Vows Improved Management Transparency As Stock Resumes Trade
Roivant Buoys Anti-Infective Portfolio With Novel iNtRON Asset
Celltrion Hit By Truxima Price Cut, Temporary Utilization Rate Drop
Yuhan Strikes Long-Awaited Lung Cancer Deal Through Huge Janssen Alliance
Biosimilar Firms Main Beneficiaries Of Korea R&D Cost Accounting Changes?
Korea Toughens Corporate Disclosure Rules To Improve R&D Transparency
SK Acquires AMPAC, On Track To Meet Global Contract Manufacturing Ambitions
GC-Yuhan Orphan Alliance Signals Changing Korean Views On Open Innovation
Kolmar Korea Eyes Pharma Expansion Via CJ HealthCare Acquisition
Korea To Examine Companies' R&D-Related Accounting For Transparency

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124347

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel